UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 高齢者における急性骨髄性白血病の治療 treatment of acute myeloid leukemia in older adults
- 2. 再発性または難治性の急性骨髄性白血病の治療 treatment of relapsed or refractory acute myeloid leukemia
- 3. 再発性および難治性の急性前骨髄球性白血病の治療 treatment of relapsed or refractory acute promyelocytic leukemia in adults
- 4. 造血細胞移植後の肝類洞閉塞症候群の治療および予防 treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation
- 5. 癌治療に用いられる治療用モノクローナル抗体に対する輸注反応 infusion reactions to therapeutic monoclonal antibodies used for cancer therapy
English Journal
- Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukaemia (AML).
- Chantepie SP, Reboursiere E, Mear JB, Gac AC, Salaun V, Benabed K, Cheze S, Johnsonansah H, Macro M, Vilque JP, Reman O.
- Leukemia & lymphoma.Leuk Lymphoma.2014 Nov 13:1-11. [Epub ahead of print]
- Abstract The prognosis of refractory/relapsed AML remains poor. Complete response (CR) rate after relapse is around 25% with 11% of patients still alive after 5 years. Efficacy and toxicity of fractionated gemtuzumab ozogamicin (fGO; 3 mg/m2, days 1, 4, 7) in combination with intensive chemotherapy
- PMID 25393676
- Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
- Koren-Michowitz M1, Maayan H, Apel A, Shem-Tov N, Yerushalmi R, Volchek Y, Avigdor A, Shimoni A, Nagler A.
- Annals of hematology.Ann Hematol.2014 Oct 14. [Epub ahead of print]
- Acute myeloid leukemia (AML) relapse is often associated with a poor outcome, especially after allogeneic stem cell transplantation (Allo-SCT). In patients relapsing early after SCT treatment, options are further limited by the fear for increased toxicity. We report our experience with ARA-C and gem
- PMID 25307457
- Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
- Daver N1, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F.
- British journal of haematology.Br J Haematol.2014 Oct 14. doi: 10.1111/bjh.13189. [Epub ahead of print]
- The clinical characteristics, treatment options and outcomes in patients with acute promyelocytic leukaemia (APL) and hyperleucocytosis remain poorly defined. This study reviewed 242 consecutive patients with APL; 29 patients (12%) had a white blood cell count (WBC) ≥ 50 × 109 /l at presentat
- PMID 25312977
Japanese Journal
- 急性骨髄性白血病(AML)に対するゲムツズマブ・オゾガマイシンの適正な使用と今後の展望 (特集 注目される造血器腫瘍に対する新規薬剤の現状と展望)
- 薄井 紀子
- 血液内科 62(1), 16-22, 2011-01
- NAID 40019064453
- Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
- CHEVALLIER Patrice,MAHE Beatrice,GARAND Richard,TALMANT Pascaline,HAROUSSEAU Jean-Luc,DELAUNAY Jacques
- International journal of hematology 88(2), 209-211, 2008-09-15
- NAID 10023969961
Related Links
- 再発性・難治性骨髄性白血病の治療薬のMylotarg (Gemtuzumab Ozogamicin)についての解説です。日本では未認可ですが、認可されている米国から個人輸入で使用が可能ですので紹介しています。掲載内容はhttp://www.fda.gov/cder/foi ...
- What are the possible side effects of gemtuzumab (Mylotarg)? Some people receiving a gemtuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel ...
Related Pictures
